Cargando…

Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease

Forty percent of non-small cell lung cancer (NSCLC) patients develop brain metastases, resulting in a dismal prognosis. However, patients in an oligo-metastatic brain disease setting seem to have better outcomes. Here, we investigate the possibility of using circulating tumor cells (CTCs) as biomark...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanssen, Annkathrin, Riebensahm, Carlotta, Mohme, Malte, Joosse, Simon A., Velthaus, Janna-Lisa, Berger, Lars Arne, Bernreuther, Christian, Glatzel, Markus, Loges, Sonja, Lamszus, Katrin, Westphal, Manfred, Riethdorf, Sabine, Pantel, Klaus, Wikman, Harriet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315958/
https://www.ncbi.nlm.nih.gov/pubmed/30572662
http://dx.doi.org/10.3390/cancers10120527
_version_ 1783384416795492352
author Hanssen, Annkathrin
Riebensahm, Carlotta
Mohme, Malte
Joosse, Simon A.
Velthaus, Janna-Lisa
Berger, Lars Arne
Bernreuther, Christian
Glatzel, Markus
Loges, Sonja
Lamszus, Katrin
Westphal, Manfred
Riethdorf, Sabine
Pantel, Klaus
Wikman, Harriet
author_facet Hanssen, Annkathrin
Riebensahm, Carlotta
Mohme, Malte
Joosse, Simon A.
Velthaus, Janna-Lisa
Berger, Lars Arne
Bernreuther, Christian
Glatzel, Markus
Loges, Sonja
Lamszus, Katrin
Westphal, Manfred
Riethdorf, Sabine
Pantel, Klaus
Wikman, Harriet
author_sort Hanssen, Annkathrin
collection PubMed
description Forty percent of non-small cell lung cancer (NSCLC) patients develop brain metastases, resulting in a dismal prognosis. However, patients in an oligo-metastatic brain disease setting seem to have better outcomes. Here, we investigate the possibility of using circulating tumor cells (CTCs) as biomarkers to differentiate oligo-metastatic patients for better risk assessment. Using the CellSearch(®) system, few CTCs were detected among NSCLC patients with brain metastases (n = 52, 12.5% ≥ two and 8.9% ≥ five CTC/7.5 mL blood) and especially oligo-metastatic brain patients (n = 34, 5.9%, and 2.9%). Still, thresholds of both ≥ two and ≥ five CTCs were independent prognostic indicators for shorter overall survival time among all of the NSCLC patients (n = 90, two CTC ≥ HR: 1.629, p = 0.024, 95% CI: 1.137–6.465 and five CTC ≥ HR: 2.846, p = 0.0304, CI: 1.104–7.339), as well as among patients with brain metastases (two CTC ≥ HR: 4.694, p = 0.004, CI: 1.650–13.354, and five CTC ≥ HR: 4.963, p = 0.003, CI: 1.752–14.061). Also, oligo-brain NSCLC metastatic patients with CTCs had a very poor prognosis (p = 0.019). Similarly, in other tumor entities, only 9.6% of patients with brain metastases (n = 52) had detectable CTCs. Our data indicate that although patients with brain metastases more seldom harbor CTCs, they are still predictive for overall survival, and CTCs might be a useful biomarker to identify oligo-metastatic NSCLC patients who might benefit from a more intense therapy.
format Online
Article
Text
id pubmed-6315958
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63159582019-01-09 Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease Hanssen, Annkathrin Riebensahm, Carlotta Mohme, Malte Joosse, Simon A. Velthaus, Janna-Lisa Berger, Lars Arne Bernreuther, Christian Glatzel, Markus Loges, Sonja Lamszus, Katrin Westphal, Manfred Riethdorf, Sabine Pantel, Klaus Wikman, Harriet Cancers (Basel) Article Forty percent of non-small cell lung cancer (NSCLC) patients develop brain metastases, resulting in a dismal prognosis. However, patients in an oligo-metastatic brain disease setting seem to have better outcomes. Here, we investigate the possibility of using circulating tumor cells (CTCs) as biomarkers to differentiate oligo-metastatic patients for better risk assessment. Using the CellSearch(®) system, few CTCs were detected among NSCLC patients with brain metastases (n = 52, 12.5% ≥ two and 8.9% ≥ five CTC/7.5 mL blood) and especially oligo-metastatic brain patients (n = 34, 5.9%, and 2.9%). Still, thresholds of both ≥ two and ≥ five CTCs were independent prognostic indicators for shorter overall survival time among all of the NSCLC patients (n = 90, two CTC ≥ HR: 1.629, p = 0.024, 95% CI: 1.137–6.465 and five CTC ≥ HR: 2.846, p = 0.0304, CI: 1.104–7.339), as well as among patients with brain metastases (two CTC ≥ HR: 4.694, p = 0.004, CI: 1.650–13.354, and five CTC ≥ HR: 4.963, p = 0.003, CI: 1.752–14.061). Also, oligo-brain NSCLC metastatic patients with CTCs had a very poor prognosis (p = 0.019). Similarly, in other tumor entities, only 9.6% of patients with brain metastases (n = 52) had detectable CTCs. Our data indicate that although patients with brain metastases more seldom harbor CTCs, they are still predictive for overall survival, and CTCs might be a useful biomarker to identify oligo-metastatic NSCLC patients who might benefit from a more intense therapy. MDPI 2018-12-19 /pmc/articles/PMC6315958/ /pubmed/30572662 http://dx.doi.org/10.3390/cancers10120527 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hanssen, Annkathrin
Riebensahm, Carlotta
Mohme, Malte
Joosse, Simon A.
Velthaus, Janna-Lisa
Berger, Lars Arne
Bernreuther, Christian
Glatzel, Markus
Loges, Sonja
Lamszus, Katrin
Westphal, Manfred
Riethdorf, Sabine
Pantel, Klaus
Wikman, Harriet
Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease
title Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease
title_full Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease
title_fullStr Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease
title_full_unstemmed Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease
title_short Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease
title_sort frequency of circulating tumor cells (ctc) in patients with brain metastases: implications as a risk assessment marker in oligo-metastatic disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315958/
https://www.ncbi.nlm.nih.gov/pubmed/30572662
http://dx.doi.org/10.3390/cancers10120527
work_keys_str_mv AT hanssenannkathrin frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease
AT riebensahmcarlotta frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease
AT mohmemalte frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease
AT joossesimona frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease
AT velthausjannalisa frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease
AT bergerlarsarne frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease
AT bernreutherchristian frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease
AT glatzelmarkus frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease
AT logessonja frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease
AT lamszuskatrin frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease
AT westphalmanfred frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease
AT riethdorfsabine frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease
AT pantelklaus frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease
AT wikmanharriet frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease